NOT-MD-20-021: Notice of Correction to Additional Information on Eligibility Number of Applications for RFA MD-20-008, "Addressing Racial Disparities in Maternal Mortality and Morbidity (R01 -Clinical Trial Optional)

Notice of Correction to Additional Information on Eligibility Number of Applications for RFA MD-20-008, "Addressing Racial Disparities in Maternal Mortality and Morbidity (R01 -Clinical Trial Optional)

Notice Number: NOT-MD-20-021

Key Dates
Release Date: May 05, 2020

Related Announcements
RFA MD-20-008 - Addressing Racial Disparities in Maternal Mortality and Morbidity (R01 Clinical Trial Optional)

Issued by
National Institute on Minority Health and Health Disparities (NIMHD)

National Heart, Lung, and Blood Institute (NHLBI)

National Institute of Nursing Research (NINR)

Purpose

The purpose of this notice is to inform potential applicants to RFA MD-20-008, "Addressing Racial Disparities in Maternal Mortality and Morbidity (R01 Clinical Trial Optional)” of a correction to remove a restriction on the number of applications per institution. Specifically, Section III. Part 3. Additional Information on Eligibility is corrected as shown below.

Current language:

Number of Applications

Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed.

The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:

A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101)

Revised language:

Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:

A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101)

All other aspects of this Funding Opportunity Announcement (FOA) remain unchanged.?

Inquiries

Please direct all inquiries to:

Beda Jean-Fran ois, Ph.D.
National Institute On Minority Health and Health Disparities (NIMHD)
Telephone: 301-594-9764
Email: [email protected]